Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Experts Warn ctDNA Testing Is Currently Inaccurate for Breast Cancer Screening and Diagnosis

Experts Warn ctDNA Testing Is Currently Inaccurate for Breast Cancer Screening and Diagnosis

November 22, 2026 Health Desk Health

“The accuracy is not sufficient for use in screening or diagnosis,” said Lt. Gen. Assoc.

Prof. Wichai Vasanasiri, a surgical oncologist and breast cancer specialist, and advisor to the Surgical Oncology Unit at Phramongkutklao Hospital. Medical experts are warning against the use of ctDNA testing for breast cancer screening, noting the technology is currently unreliable for early diagnosis. Wichai explained that breast cancer cells can enter the bloodstream even from small tumors, but their presence does not guarantee that a patient has cancer. Conversely, a negative test result does not confirm the absence of disease, as some patients with cancer may not test positive for ctDNA. The medical community previously utilized Circulating Tumor Cell (CTC) testing, which involved spinning blood samples to isolate cells, according to bangkokbiznews. However, this method proved costly and offered limited practical utility. Modern efforts shifted toward detecting fragments of DNA released into the bloodstream when cancer cells die, known as ctDNA.

In theory, ctDNA was intended for three purposes: screening and diagnosis, determining if a patient is cancer-free, and monitoring treatment responses. Currently, the medical consensus limits its use to the latter. “The only real benefit at present is monitoring during treatment,” Wichai told bangkokbiznews. He said that physicians can establish a baseline blood test before therapy and compare it to subsequent results.

A declining ctDNA level indicates that treatment is effective, though rising levels during follow-up remain a “gray area” regarding the confirmation of recurrence. Wichai advised against using ctDNA to confirm a cancer diagnosis or to declare a patient cancer-free, as hidden cells may remain undetected by current molecular analysis.

The specificity of current DNA-level testing is not yet high enough to replace the standard screening methods that have long been the foundation of breast cancer care.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • Linnemann Rejects Flu Vaccine Shortage Claims as Germany Confirms 20.2 Million Doses
  • Apple Prepares 9 Devices for Spring 2027: iPhones, iPads, MacBooks (Report)
  • Jessie J Returns to Instagram After Breast Reconstruction Surgery (newsdirectory3.com)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service